TW201043638A - Compositions and methods for antibodies targeting complement protein C3b - Google Patents

Info

Publication number

TW201043638A

TW201043638A TW099114417A TW99114417A TW201043638A TW 201043638 A TW201043638 A TW 201043638A TW 099114417 A TW099114417 A TW 099114417A TW 99114417 A TW99114417 A TW 99114417A TW 201043638 A TW201043638 A TW 201043638A

Authority

TW

Taiwan

Prior art keywords

antibody

antigen

seq

sequence

binding fragment

Prior art date

2009-05-06

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title abstract description 143
• 239000000203 mixture Substances 0.000 title abstract description 38
• 230000008685 targeting Effects 0.000 title 1
• 230000027455 binding Effects 0.000 claims abstract description 423
• 239000000427 antigen Substances 0.000 claims abstract description 256
• 241000282414 Homo sapiens Species 0.000 claims abstract description 254
• 108091007433 antigens Proteins 0.000 claims abstract description 254
• 102000036639 antigens Human genes 0.000 claims abstract description 254
• 239000012634 fragment Substances 0.000 claims abstract description 218
• 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 441
• 102100022133 Complement C3 Human genes 0.000 claims description 428
• 210000004027 cell Anatomy 0.000 claims description 120
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
• 230000000295 complement effect Effects 0.000 claims description 64
• 150000007523 nucleic acids Chemical class 0.000 claims description 61
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
• 230000024203 complement activation Effects 0.000 claims description 59
• 238000012360 testing method Methods 0.000 claims description 53
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 52
• 229920001184 polypeptide Polymers 0.000 claims description 50
• 102000039446 nucleic acids Human genes 0.000 claims description 43
• 108020004707 nucleic acids Proteins 0.000 claims description 43
• 210000004602 germ cell Anatomy 0.000 claims description 39
• 206010018910 Haemolysis Diseases 0.000 claims description 35
• 230000008588 hemolysis Effects 0.000 claims description 34
• 230000005764 inhibitory process Effects 0.000 claims description 34
• 239000013598 vector Substances 0.000 claims description 33
• 241000282553 Macaca Species 0.000 claims description 31
• 238000004519 manufacturing process Methods 0.000 claims description 31
• 230000035772 mutation Effects 0.000 claims description 30
• 230000014509 gene expression Effects 0.000 claims description 28
• 230000008021 deposition Effects 0.000 claims description 27
• 239000003814 drug Substances 0.000 claims description 25
• 208000002780 macular degeneration Diseases 0.000 claims description 24
• 229940079593 drug Drugs 0.000 claims description 16
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 15
• 238000000338 in vitro Methods 0.000 claims description 15
• 108010078015 Complement C3b Proteins 0.000 claims description 14
• 230000000890 antigenic effect Effects 0.000 claims description 14
• 210000004962 mammalian cell Anatomy 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 12
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
• 108020004511 Recombinant DNA Proteins 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 230000001419 dependent effect Effects 0.000 claims description 5
• 239000012528 membrane Substances 0.000 claims description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
• 108090000623 proteins and genes Proteins 0.000 description 124
• 102000004169 proteins and genes Human genes 0.000 description 107
• 235000018102 proteins Nutrition 0.000 description 103
• 125000003275 alpha amino acid group Chemical group 0.000 description 94
• 238000003556 assay Methods 0.000 description 76
• 235000001014 amino acid Nutrition 0.000 description 62
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 59
• 229940024606 amino acid Drugs 0.000 description 54
• 210000002966 serum Anatomy 0.000 description 51
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 49
• 150000001413 amino acids Chemical class 0.000 description 49
• 239000011324 bead Substances 0.000 description 47
• 238000004091 panning Methods 0.000 description 45
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 43
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 43
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 43
• 230000000694 effects Effects 0.000 description 38
• 239000002953 phosphate buffered saline Substances 0.000 description 37
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 36
• 108060003951 Immunoglobulin Proteins 0.000 description 32
• 239000000872 buffer Substances 0.000 description 32
• 239000000499 gel Substances 0.000 description 32
• 102000018358 immunoglobulin Human genes 0.000 description 32
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 30
• 238000006243 chemical reaction Methods 0.000 description 30
• 239000000523 sample Substances 0.000 description 28
• 238000002965 ELISA Methods 0.000 description 27
• 239000000243 solution Substances 0.000 description 27
• 239000002253 acid Substances 0.000 description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
• 239000003795 chemical substances by application Substances 0.000 description 25
• 239000013604 expression vector Substances 0.000 description 25
• 238000012216 screening Methods 0.000 description 25
• 230000008878 coupling Effects 0.000 description 23
• 238000010168 coupling process Methods 0.000 description 23
• 238000005859 coupling reaction Methods 0.000 description 23
• 206010057190 Respiratory tract infections Diseases 0.000 description 22
• 239000003085 diluting agent Substances 0.000 description 22
• 239000000047 product Substances 0.000 description 21
• 238000000746 purification Methods 0.000 description 21
• 206010036790 Productive cough Diseases 0.000 description 20
• 229960002685 biotin Drugs 0.000 description 20
• 239000011616 biotin Substances 0.000 description 20
• UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 20
• 201000010099 disease Diseases 0.000 description 20
• -1 noractucine Chemical compound 0.000 description 20
• 229920001223 polyethylene glycol Polymers 0.000 description 20
• 208000024794 sputum Diseases 0.000 description 20
• 230000001225 therapeutic effect Effects 0.000 description 20
• 239000002202 Polyethylene glycol Substances 0.000 description 19
• 230000006870 function Effects 0.000 description 19
• 239000000126 substance Substances 0.000 description 19
• 238000011282 treatment Methods 0.000 description 19
• 235000020958 biotin Nutrition 0.000 description 18
• 230000037361 pathway Effects 0.000 description 18
• 210000003802 sputum Anatomy 0.000 description 18
• 108090000056 Complement factor B Proteins 0.000 description 17
• 230000004913 activation Effects 0.000 description 17
• 210000003743 erythrocyte Anatomy 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 230000002401 inhibitory effect Effects 0.000 description 17
• 239000006228 supernatant Substances 0.000 description 17
• 108020004705 Codon Proteins 0.000 description 16
• 102000003712 Complement factor B Human genes 0.000 description 16
• 229920001213 Polysorbate 20 Polymers 0.000 description 16
• 230000004927 fusion Effects 0.000 description 16
• 230000013595 glycosylation Effects 0.000 description 16
• 238000006206 glycosylation reaction Methods 0.000 description 16
• 125000003729 nucleotide group Chemical group 0.000 description 16
• 108091033319 polynucleotide Proteins 0.000 description 16
• 102000040430 polynucleotide Human genes 0.000 description 16
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 16
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 16
• 238000006467 substitution reaction Methods 0.000 description 16
• 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 15
• 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 15
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 15
• 238000005516 engineering process Methods 0.000 description 15
• 230000004048 modification Effects 0.000 description 15
• 238000012986 modification Methods 0.000 description 15
• 239000002157 polynucleotide Substances 0.000 description 15
• 238000005406 washing Methods 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 14
• 238000010790 dilution Methods 0.000 description 14
• 239000012895 dilution Substances 0.000 description 14
• 238000002372 labelling Methods 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• 230000000903 blocking effect Effects 0.000 description 13
• 239000003153 chemical reaction reagent Substances 0.000 description 13
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 229920000392 Zymosan Polymers 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• 229920000936 Agarose Polymers 0.000 description 11
• 102000000989 Complement System Proteins Human genes 0.000 description 11
• 108010069112 Complement System Proteins Proteins 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 230000004154 complement system Effects 0.000 description 11
• 238000011534 incubation Methods 0.000 description 11
• 231100000350 mutagenesis Toxicity 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 108010067306 Fibronectins Proteins 0.000 description 10
• 102000016359 Fibronectins Human genes 0.000 description 10
• 241000282412 Homo Species 0.000 description 10
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 241000283973 Oryctolagus cuniculus Species 0.000 description 10
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 10
• 238000005119 centrifugation Methods 0.000 description 10
• 238000003776 cleavage reaction Methods 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 230000006698 induction Effects 0.000 description 10
• 239000003112 inhibitor Substances 0.000 description 10
• 239000001573 invertase Substances 0.000 description 10
• 235000011073 invertase Nutrition 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 229920000642 polymer Polymers 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 230000001603 reducing effect Effects 0.000 description 10
• 230000007017 scission Effects 0.000 description 10
• 239000007790 solid phase Substances 0.000 description 10
• 108010078791 Carrier Proteins Proteins 0.000 description 9
• 241000588724 Escherichia coli Species 0.000 description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 230000009089 cytolysis Effects 0.000 description 9
• 230000007850 degeneration Effects 0.000 description 9
• 108020001507 fusion proteins Proteins 0.000 description 9
• 102000037865 fusion proteins Human genes 0.000 description 9
• 230000001105 regulatory effect Effects 0.000 description 9
• 102000014914 Carrier Proteins Human genes 0.000 description 8
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 239000011230 binding agent Substances 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 239000003623 enhancer Substances 0.000 description 8
• 229940050526 hydroxyethylstarch Drugs 0.000 description 8
• 235000013336 milk Nutrition 0.000 description 8
• 239000008267 milk Substances 0.000 description 8
• 210000004080 milk Anatomy 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 239000012723 sample buffer Substances 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 101000693922 Bos taurus Albumin Proteins 0.000 description 7
• 108010090804 Streptavidin Proteins 0.000 description 7
• 241000700605 Viruses Species 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000001580 bacterial effect Effects 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 7
• 238000002825 functional assay Methods 0.000 description 7
• 125000005647 linker group Chemical group 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 230000009261 transgenic effect Effects 0.000 description 7
• 108010088751 Albumins Proteins 0.000 description 6
• 102000009027 Albumins Human genes 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• 238000002835 absorbance Methods 0.000 description 6
• 230000009824 affinity maturation Effects 0.000 description 6
• 150000001412 amines Chemical group 0.000 description 6
• 239000012491 analyte Substances 0.000 description 6
• 230000001588 bifunctional effect Effects 0.000 description 6
• 238000012875 competitive assay Methods 0.000 description 6
• 230000002860 competitive effect Effects 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 229920003023 plastic Polymers 0.000 description 6
• 239000004033 plastic Substances 0.000 description 6
• 238000003127 radioimmunoassay Methods 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 238000007910 systemic administration Methods 0.000 description 6
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 5
• 206010069754 Acquired gene mutation Diseases 0.000 description 5
• 241000282693 Cercopithecidae Species 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• 102000019298 Lipocalin Human genes 0.000 description 5
• 108050006654 Lipocalin Proteins 0.000 description 5
• 239000004743 Polypropylene Substances 0.000 description 5
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
• 239000006180 TBST buffer Substances 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
• 125000003277 amino group Chemical group 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 238000000576 coating method Methods 0.000 description 5
• 230000021615 conjugation Effects 0.000 description 5
• 230000009260 cross reactivity Effects 0.000 description 5
• 230000001186 cumulative effect Effects 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
• 229910052737 gold Inorganic materials 0.000 description 5
• 239000010931 gold Substances 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 229910001629 magnesium chloride Inorganic materials 0.000 description 5
• 230000005291 magnetic effect Effects 0.000 description 5
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 239000008188 pellet Substances 0.000 description 5
• 210000002706 plastid Anatomy 0.000 description 5
• 229920001155 polypropylene Polymers 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 230000037439 somatic mutation Effects 0.000 description 5
• 239000012089 stop solution Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 238000004448 titration Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• 239000013603 viral vector Substances 0.000 description 5
• FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
• 229920001817 Agar Polymers 0.000 description 4
• 102000008102 Ankyrins Human genes 0.000 description 4
• 108010049777 Ankyrins Proteins 0.000 description 4
• 241000282836 Camelus dromedarius Species 0.000 description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 206010025421 Macule Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 241001494479 Pecora Species 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 108700019146 Transgenes Proteins 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 239000008272 agar Substances 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
• 239000012472 biological sample Substances 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000012512 characterization method Methods 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 230000000052 comparative effect Effects 0.000 description 4
• 231100000599 cytotoxic agent Toxicity 0.000 description 4
• 238000000354 decomposition reaction Methods 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 238000011033 desalting Methods 0.000 description 4
• 238000012377 drug delivery Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 229910021645 metal ion Inorganic materials 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 239000000178 monomer Substances 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 201000008383 nephritis Diseases 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 238000005457 optimization Methods 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000002741 site-directed mutagenesis Methods 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1h-naphthalene-8,2'-3h-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 description 3
• 235000002198 Annona diversifolia Nutrition 0.000 description 3
• 201000004569 Blindness Diseases 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 102100022002 CD59 glycoprotein Human genes 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 102100030886 Complement receptor type 1 Human genes 0.000 description 3
• 102000009109 Fc receptors Human genes 0.000 description 3
• 108010087819 Fc receptors Proteins 0.000 description 3
• 241000287828 Gallus gallus Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 3
• 238000012450 HuMAb Mouse Methods 0.000 description 3
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• 241000282842 Lama glama Species 0.000 description 3
• 102100039373 Membrane cofactor protein Human genes 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 241000255972 Pieris <butterfly> Species 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 108090000848 Ubiquitin Proteins 0.000 description 3
• 102000044159 Ubiquitin Human genes 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000012131 assay buffer Substances 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 235000013330 chicken meat Nutrition 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 239000004020 conductor Substances 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 208000011325 dry age related macular degeneration Diseases 0.000 description 3
• 239000000428 dust Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000004438 eyesight Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 102000046949 human MSC Human genes 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000002974 pharmacogenomic effect Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 239000002002 slurry Substances 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 235000012431 wafers Nutrition 0.000 description 3
• 229910052727 yttrium Inorganic materials 0.000 description 3
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 3
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 108010000239 Aequorin Proteins 0.000 description 2
• RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 241000193830 Bacillus <bacterium> Species 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 102400000584 C31 Human genes 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 102100032768 Complement receptor type 2 Human genes 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 2
• 208000037312 Familial drusen Diseases 0.000 description 2
• 206010016717 Fistula Diseases 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 101100440311 Homo sapiens C5 gene Proteins 0.000 description 2
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 2
• 238000012449 Kunming mouse Methods 0.000 description 2
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
• 241000282838 Lama Species 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 2
• 239000008118 PEG 6000 Substances 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 201000007737 Retinal degeneration Diseases 0.000 description 2
• 208000032437 Retinal deposits Diseases 0.000 description 2
• 206010038848 Retinal detachment Diseases 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 241000239226 Scorpiones Species 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 108020005038 Terminator Codon Proteins 0.000 description 2
• 101710120037 Toxin CcdB Proteins 0.000 description 2
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000021917 activation of membrane attack complex Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 230000009830 antibody antigen interaction Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 229960002319 barbital Drugs 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 238000009534 blood test Methods 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 230000002612 cardiopulmonary effect Effects 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 229960005091 chloramphenicol Drugs 0.000 description 2
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 210000003161 choroid Anatomy 0.000 description 2
• 102000006834 complement receptors Human genes 0.000 description 2
• 108010047295 complement receptors Proteins 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 201000006754 cone-rod dystrophy Diseases 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000007872 degassing Methods 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 230000003890 fistula Effects 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000033581 fucosylation Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 229940127121 immunoconjugate Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 238000012933 kinetic analysis Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000001071 malnutrition Effects 0.000 description 2
• 235000000824 malnutrition Nutrition 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 229920005615 natural polymer Polymers 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 239000000700 radioactive tracer Substances 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 230000004258 retinal degeneration Effects 0.000 description 2
• 230000004264 retinal detachment Effects 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 102220077433 rs797044910 Human genes 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 238000010187 selection method Methods 0.000 description 2
• 239000006152 selective media Substances 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 238000012289 standard assay Methods 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000012536 storage buffer Substances 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000000052 vinegar Substances 0.000 description 2
• 235000021419 vinegar Nutrition 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
• MHVJRKBZMUDEEV-APQLOABGSA-N (+)-Pimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-APQLOABGSA-N 0.000 description 1
• MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 description 1
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• FTMJFHVKAXPFIY-RKDXNWHRSA-N 2,2-dichloro-n-[(1r,2r)-1,3-dihydroxy-1-(3-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=CC([N+]([O-])=O)=C1 FTMJFHVKAXPFIY-RKDXNWHRSA-N 0.000 description 1
• MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
• 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
• UDPCXVIKHFVPSZ-HOIFWPIMSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O UDPCXVIKHFVPSZ-HOIFWPIMSA-N 0.000 description 1
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000881711 Acipenser sturio Species 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
• PXFBZOLANLWPMH-SMLHJDAJSA-N Affinine Chemical group C1C(C2=CC=CC=C2N2)=C2C(=O)C[C@@H]2C(=C/C)\CN(C)[C@H]1C2CO PXFBZOLANLWPMH-SMLHJDAJSA-N 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
• 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 235000003826 Artemisia Nutrition 0.000 description 1
• 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
• 240000006891 Artemisia vulgaris Species 0.000 description 1
• 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 241000589562 Brucella Species 0.000 description 1
• 108010055167 CD59 Antigens Proteins 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• 101100494266 Caenorhabditis elegans best-17 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282828 Camelus bactrianus Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 229920002160 Celluloid Polymers 0.000 description 1
• 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 241000581364 Clinitrachus argentatus Species 0.000 description 1
• 102000003780 Clusterin Human genes 0.000 description 1
• 108090000197 Clusterin Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108090000955 Complement C2 Proteins 0.000 description 1
• 108010028780 Complement C3 Proteins 0.000 description 1
• 102100034622 Complement factor B Human genes 0.000 description 1
• 102000003706 Complement factor D Human genes 0.000 description 1
• 108090000059 Complement factor D Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 101000746263 Conus leopardus Conotoxin Lp5.1 Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 102000014824 Crystallins Human genes 0.000 description 1
• 108010064003 Crystallins Proteins 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 210000004128 D cell Anatomy 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
• IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
• 241000086550 Dinosauria Species 0.000 description 1
• 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102100040646 Fc receptor-like B Human genes 0.000 description 1
• 101710142642 Fc receptor-like B Proteins 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102000006471 Fucosyltransferases Human genes 0.000 description 1
• 108010019236 Fucosyltransferases Proteins 0.000 description 1
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000051366 Glycosyltransferases Human genes 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 108010006464 Hemolysin Proteins Proteins 0.000 description 1
• 208000000616 Hemoptysis Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000003623 Hypoalbuminemia Diseases 0.000 description 1
• 208000020060 Increased inflammatory response Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000010415 Low Vision Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 239000012515 MabSelect SuRe Substances 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
• 208000035719 Maculopathy Diseases 0.000 description 1
• 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
• 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
• 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
• 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 101710146216 Membrane cofactor protein Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
• ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
• 240000002769 Morchella esculenta Species 0.000 description 1
• 235000002779 Morchella esculenta Nutrition 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• 208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000034247 Pattern dystrophy Diseases 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 241000243142 Porifera Species 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 229910052774 Proactinium Inorganic materials 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
• 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 208000006193 Pulmonary infarction Diseases 0.000 description 1
• 206010037457 Pulmonary vasculitis Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000710961 Semliki Forest virus Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000116133 Siphonodictyon coralliphagum Species 0.000 description 1
• 240000006394 Sorghum bicolor Species 0.000 description 1
• 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
• 241001279361 Stachybotrys Species 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 244000297179 Syringa vulgaris Species 0.000 description 1
• 235000004338 Syringa vulgaris Nutrition 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 101710192266 Tegument protein VP22 Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000282840 Vicugna vicugna Species 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000006154 adenylylation Effects 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000003314 affinity selection Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000009418 agronomic effect Effects 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• OQXCFOKEAFQNJL-UHFFFAOYSA-N amino diethyl phosphate Chemical compound CCOP(=O)(ON)OCC OQXCFOKEAFQNJL-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000002391 anti-complement effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 108010008730 anticomplement Proteins 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229910052787 antimony Inorganic materials 0.000 description 1
• WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009052 artemisia Nutrition 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000004900 autophagic degradation Effects 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 230000003796 beauty Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 210000001775 bruch membrane Anatomy 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000008709 cellular rearrangement Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 239000002817 coal dust Substances 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 230000004452 decreased vision Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000000385 dialysis solution Substances 0.000 description 1
• 229910000071 diazene Inorganic materials 0.000 description 1
• 235000021196 dietary intervention Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• VXFFWFGRYJESOH-UHFFFAOYSA-N diphosphanium phthalate Chemical compound C(C=1C(C(=O)[O-])=CC=CC1)(=O)[O-].[PH4+].[PH4+] VXFFWFGRYJESOH-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000012407 engineering method Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 210000000540 fraction c Anatomy 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 201000006321 fundus dystrophy Diseases 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 101150023212 fut8 gene Proteins 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000004519 grease Substances 0.000 description 1
• DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
• 229960002867 griseofulvin Drugs 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 208000006750 hematuria Diseases 0.000 description 1
• 239000003228 hemolysin Substances 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000004371 high visual acuity Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000054751 human RUNX1T1 Human genes 0.000 description 1
• 210000000688 human artificial chromosome Anatomy 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 150000002431 hydrogen Chemical group 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
• XAKRTGZVYPZHCO-UHFFFAOYSA-O hydroxy-methoxy-oxophosphanium Chemical group CO[P+](O)=O XAKRTGZVYPZHCO-UHFFFAOYSA-O 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000004377 improving vision Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 208000005430 kidney cortex necrosis Diseases 0.000 description 1
• 238000003367 kinetic assay Methods 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000003975 mesenteric artery Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 229910052750 molybdenum Inorganic materials 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000002539 nanocarrier Substances 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 238000002577 ophthalmoscopy Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960003407 pegaptanib Drugs 0.000 description 1
• JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
• 238000005897 peptide coupling reaction Methods 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 230000006267 polysialylation Effects 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 238000011176 pooling Methods 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 201000006301 pulmonary embolism and infarction Diseases 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000013878 renal filtration Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 230000005070 ripening Effects 0.000 description 1
• 102220090920 rs771027745 Human genes 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• 238000009991 scouring Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 238000011524 similarity measure Methods 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000004291 sulphur dioxide Substances 0.000 description 1
• 235000010269 sulphur dioxide Nutrition 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 235000015149 toffees Nutrition 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000012448 transchromosomic mouse model Methods 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 238000012451 transgenic animal system Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1